

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WANJIA GROUP HOLDINGS LIMITED

萬嘉集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 401)

INSIDE INFORMATION

PROFIT WARNING

The Announcement is made by Wanjia Group Holdings Limited (the “**Company**”, together with its subsidiaries collectively refer to as the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2022 (the “**Current Period**”) and other information currently available to the Company, it is expected that the loss for the Current Period will increase substantially by not less than approximately HK\$2 million as compared to the profit of approximately HK\$0.468 million recorded for the six months ended 30 September 2021. The expected increase in loss for the Current Period was mainly attributable to, among others, the following reasons:

With a new wave of Covid-19 pandemic raging through Mainland China since the first quarter of 2022, strict quarantine measures and lockdown restrictions implemented in some of the cities have caused disruptions to the supply chain and manufacturing activities, adversely affecting the cost of sales of the Group. Moreover, the increase of production costs due to a rise in prices of key raw materials, which led to substantial increase in cost of sales and thus the Group’s overall profitability in pharmaceutical distribution and hemodialysis services have been negatively impacted for the Current Period.

The Company is still in the process of finalizing the unaudited consolidated interim results of the Group for the six months ended 30 September 2022. Hence, the information disclosed in this announcement only represents a preliminary assessment by the Board and the management of the Group based on the information currently available to them, which have not yet been reviewed by the audit committee of the Company. The unaudited consolidated interim results of the Group may differ from the information contained in this announcement which are subject to adjustments. Shareholders and potential investors of the Company are advised to read carefully the unaudited consolidated interim results announcement of the Group for the six months ended 30 September 2022, which is expected to be published in on 23 November 2022 in compliance with the requirements under the Listing Rules.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares or other securities of the Company.

By order of the Board
Wanjia Group Holdings Limited
Wang Jia Jun

Chief Executive Officer and Executive Director

Hong Kong, 9 November 2022

As at the date of this announcement, the Board comprises one executive Director, namely Mr. Wang Jia Jun, one non-executive Director, namely Dr. Xiao Zhixin, and three independent non-executive Directors, namely Mr. Wong Hon Kit, Dr. Liu Yongping and Mr. Ho Man.